Submitted by Nicola-Swanborough on Thu, 15/03/2018 - 13:19
The Charity Tax Commission has launched a consultation seeking views on whether and how the tax treatment of charities - estimated to be worth around £3.7bn a year - needs to be reformed.
Submitted by Nicola-Swanborough on Mon, 12/02/2018 - 17:03
New measures to avoid the exposure of unborn babies to the epilepsy drug, sodium valproate have been announced by the safety committee of the European Medicines Agency (EMA).
Submitted by Nicola-Swanborough on Tue, 09/01/2018 - 10:55
Epilepsy Society's chief executive Clare Pelham has joined the Sodium Valproate Expert Working Group which supports the Government's Commission on Human Medicines.
Submitted by Nicola-Swanborough on Mon, 08/01/2018 - 16:09
Epilepsy Society's chief executive Clare Pelham looks back over the year, at the highs and - sadly - a very snowy low.
Submitted by Nicola-Swanborough on Thu, 26/10/2017 - 13:31
Our content manager, Nicola Swanborough, explains how our sodium valproate survey helped us raise awareness of risks associated with the drug in the media, parliament and with Government.
Submitted by Nicola-Swanborough on Thu, 19/10/2017 - 19:10
Although we could not see them as we watched today's sodium valproate debate via Parliament Live TV, the presence of three women -Janet Williams, Emma Murphy and Deborah Mann - as they sat in the public gallery, was very much felt in the House of Commons.
Submitted by Nicola-Swanborough on Thu, 19/10/2017 - 11:45
Epilepsy Society's chief executive, Clare Pelham, has welcomed a second letter from the Department of Health in response to her letter to health secretary Jeremy Hunt, calling for mandatory reviews for women and girls of childbearing age taking sodium valproate.
Submitted by carl-charlesworth on Wed, 27/09/2017 - 15:17
Epilepsy Society's chief executive Clare Pelham wins an honorary degree of doctor of the university from the Open University for her work around people with disabilities.
Submitted by carl-charlesworth on Mon, 23/01/2017 - 16:14
Epilepsy Society's Chief Executive Clare Pelham is encouraged that the health of patients is being put ahead of business after the Competition Appeal Tribunal refused to suspend the Competition Markets Authority's ruling that they had to reduce the price of phenytoin sodium capsules by today.
Submitted by helen-skipworth on Tue, 17/01/2017 - 16:23
Epilepsy Society's chief executive Clare Pelham has expressed frustration that pharmaceutical company Flynn Pharma has failed to reassure her of their long-term commitment to supplying the epilepsy drug, phenytoin sodium capsules.